Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002314247 | SCV000738650 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2016-12-06 | criteria provided, single submitter | clinical testing | The p.P435L variant (also known as c.1304C>T), located in coding exon 8 of the COL5A1 gene, results from a C to T substitution at nucleotide position 1304. The proline at codon 435 is replaced by leucine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV002232760 | SCV001497513 | benign | Ehlers-Danlos syndrome, classic type, 1 | 2023-09-17 | criteria provided, single submitter | clinical testing | |
Johns Hopkins Genomics, |
RCV002232760 | SCV002570402 | uncertain significance | Ehlers-Danlos syndrome, classic type, 1 | 2022-06-28 | criteria provided, single submitter | clinical testing | This COL5A1 variant (rs772379819) is rare (<0.1%) in a large population dataset (gnomAD: 10/280002 total alleles; 0.004%; no homozygotes) and has been reported in ClinVar. Three bioinformatic tools queried predict that this substitution would be damaging, and the proline residue at this position is strongly evolutionarily conserved across the vertebrate species assessed. Bioinformatic analysis predicts that this variant would not affect normal exon 8 splicing, although this has not been confirmed experimentally to our knowledge. Due to insufficient evidence, we consider the clinical significance of c.1304C>T to be uncertain at this time. |
Fulgent Genetics, |
RCV002491326 | SCV002794537 | uncertain significance | Ehlers-Danlos syndrome, classic type, 1; Fibromuscular dysplasia, multifocal | 2021-10-11 | criteria provided, single submitter | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV001573546 | SCV001799575 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001573546 | SCV001965848 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Genome |
RCV003483689 | SCV004228690 | not provided | Ehlers-Danlos syndrome, classic type, 2; Ehlers-Danlos syndrome, classic type, 1 | no assertion provided | phenotyping only | Variant interpreted as Uncertain significance and reported on 01-13-2020 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |